Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rusnano, Nearmedic Plus to set up pharmaceutical manufacturing facility
The facilities will be set up in Obninsk, in Kaluga Oblas and the production is likely to begin in late 2013. The manufacturing process will include entire cycle
The facilities will be set up in Obninsk, in Kaluga Oblas and the production is likely to begin in late 2013. The manufacturing process will include entire cycle
CCX168 specifically targets the C5a receptor, a pro-inflammatory mediator that is involved in AAV as well as other autoimmune diseases. The randomized, double-blind, placebo-controlled trial will assess the
Warner Chilcott (US) and Warner Chilcott Company had filed suit against Watson seeking to prevent Watson from commercializing its product. The lawsuit which was filed under the provisions
DrugLogic’s Qscan product monitors patient, adverse event, claims, outcomes and publicly available data sources. As per the terms of the collaboration, GPRD will allow DrugLogic to format and
According to the company, the features of the new software help improve product safety and demonstrate long-term treatment efficacy. In addition, the user-friendly software has increased scalability to
Revco freezers comprise an intuitive on-board computer which includes an icon-driven touch-screen control panel for easy access to a host of monitoring and control information. By the freezers
The EnPresso Y Defined is a pre-sterilized tablet having an extended shelf-life and can be added directly to sterile water to create an instant microbial medium ready for
Following the deal, Abgent would bring new product lines of biological research reagents for drug discovery and basic research to WuXi. Abgent utilizes production facilities consisting of a
JHU has established the Johns Hopkins Brain Science Institute (JHBSi) which is held in translational research. As per the signed agreement, JHBSi will provide Eisai with neurological drug
The approval followed previously conducted trials enrolling patients with transfusional iron overload and evidence of inadequate iron removal despite previous treatment with deferoxamine. The standard of care to